We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Commentary to the Article Metabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort.
- Authors
Teng, Ethan Yen-Hua; Liao, Karen Chia-Wen; Chang, Yi-Cheng
- Abstract
It is quite interesting to notice that the overall incidence of preclinical HF is 46-68% at the end of follow-up, which may be related to the inclusion of NT-proBNP in the diagnosis of preclinical HF. According to the contemporary professional consensus, heart failure (HF) is not an organic pathological diagnosis, but a clinical syndrome defined by symptoms and signs [[1]]. Even so, the STANISLAS cohort study is internationally the only longitudinal family cohort of subjects who are presumed to be healthy and gave us an excellent insight into the relationship between metabolic syndrome and HF [[8]].
- Subjects
HEART failure; METABOLIC syndrome; SYMPTOMS
- Publication
Cardiology, 2022, Vol 147, Issue 3, p288
- ISSN
0008-6312
- Publication type
Article
- DOI
10.1159/000523819